FGFR1 and neoplasm: The patient was diagnosed with progressive disease 3 months after surgery and treated under the NCI-Children’s Oncology Group (COG) MATCH Study with Erdafitinib, an FGFR1 inhibitor, which initiated tumor response but was not tolerated by the patient.